Assertio Holdings, Inc. (ASRT)

NASDAQ: ASRT · Real-Time Price · USD
0.6917
-0.0292 (-4.05%)
At close: Mar 28, 2025, 4:00 PM
0.7004
+0.0087 (1.26%)
After-hours: Mar 28, 2025, 7:49 PM EDT
-4.05%
Market Cap 66.25M
Revenue (ttm) 124.96M
Net Income (ttm) -21.58M
Shares Out 95.77M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 527,476
Open 0.7210
Previous Close 0.7209
Day's Range 0.6795 - 0.7300
52-Week Range 0.6795 - 1.8000
Beta 0.81
Analysts Strong Buy
Price Target 3.08 (+345.28%)
Earnings Date Mar 12, 2025

About ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of ag... [Read more]

Sector Healthcare
IPO Date Nov 5, 1997
Employees 53
Stock Exchange NASDAQ
Ticker Symbol ASRT
Full Company Profile

Financial Performance

In 2024, Assertio Holdings's revenue was $124.96 million, a decrease of -17.83% compared to the previous year's $152.07 million. Losses were -$21.58 million, -93.50% less than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ASRT stock is "Strong Buy." The 12-month stock price forecast is $3.08, which is an increase of 345.28% from the latest price.

Price Target
$3.08
(345.28% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present a...

8 days ago - GlobeNewsWire

Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript

Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Partici...

16 days ago - Seeking Alpha

Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Oper...

16 days ago - GlobeNewsWire

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financ...

23 days ago - GlobeNewsWire

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...

3 months ago - GlobeNewsWire

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...

3 months ago - GlobeNewsWire

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...

3 months ago - GlobeNewsWire

Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its long equit...

4 months ago - Business Wire

Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript

Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associate...

4 months ago - Seeking Alpha

Assertio Reports Third Quarter 2024 Financial Results

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -...

4 months ago - GlobeNewsWire

Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long equity pos...

4 months ago - Business Wire

Assertio Provides Response to Letter from Short-seller

Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Ta...

4 months ago - GlobeNewsWire

Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has now inverted its long equity...

5 months ago - Business Wire

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...

6 months ago - GlobeNewsWire

Assertio Holdings: Management Change Could Improve Comeback Chances

After losing exclusivity with its prior flagship drug, pharma firm Assertio Holdings (ASRT) is angling for a comeback with a new flagship drug product. However, Assertio's latest fiscal results were m...

7 months ago - Seeking Alpha

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering...

7 months ago - GlobeNewsWire

Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript

Assertio Holdings, Inc. (NASDAQ:ASRT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - Chief Executive Officer A...

8 months ago - Seeking Alpha

Assertio Reports Second Quarter 2024 Financial Results

Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments In...

8 months ago - GlobeNewsWire

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...

8 months ago - GlobeNewsWire

Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc., a significant shareholder of Assertio Holdings, Inc. (NASDAQ: ASRT), today issued the following letter to the company's Board of Directors. ...

8 months ago - Business Wire

Assertio: An Extremely Asymmetric Bet Skewed To The Upside

Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharma...

9 months ago - Seeking Alpha

Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024

LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...

10 months ago - GlobeNewsWire

Assertio to Participate in Benchmark Healthcare Conference on May 21-22

LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering d...

11 months ago - GlobeNewsWire

BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS

Letter Expresses Several Significant Concerns and Recommends That Further Investigation is Warranted Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Ei...

11 months ago - PRNewsWire

Assertio to Participate in AGP Healthcare Conference on May 21

LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering d...

11 months ago - GlobeNewsWire